Stimulating Catheter for Lumbar Plexus Block: Better Postoperative Analgesia?

NCT ID: NCT02162121

Last Updated: 2017-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Stimulating catheters have been introduced to reduce the incidence of secondary failure after continuous peripheral nerve blocks, but they effectiveness over traditional nonstimulating catheters is still controversial. The aim of this prospective, randomized, blinded study is to detect if stimulating catheters improve postoperative compared with conventional non-stimulating catheters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip Replacement Arthroplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stimulating catheter

After Spinal Anesthesia (Levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with stimulating catheter ("Stimolong", "Pajunk", Germany). Mepivacaine 1% 15 ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated.

Group Type EXPERIMENTAL

Continuous lumbar plexus: stimulating catheter

Intervention Type PROCEDURE

Perinervous stimulating catheter ("Stimulong", "Pajunk", Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia.

Spinal Anesthesia

Intervention Type PROCEDURE

Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.

Local anesthetic infusion

Intervention Type PROCEDURE

Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day

Intravenous analgesia

Intervention Type PROCEDURE

Ketorolac 30mg 3 times a day

Opioids rescue analgesia

Intervention Type PROCEDURE

Buprenorphine 0,2mg twice a day if VAS\>4

Mepivacaine 1%

Intervention Type DRUG

Levobupivacaine 0,5%

Intervention Type DRUG

Ropivacaine 0,2%

Intervention Type DRUG

Ketorolac 30mg

Intervention Type DRUG

Buprenorphine 0,2mg

Intervention Type DRUG

Stimulong, Pajunk, Germany.

Intervention Type DEVICE

Non-stimulating catheter

After Spinal Anesthesia (levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with non-stimulating catheter ("Stimolong", "Pajunk", Germany). Mepivacaine 1% 15ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated.

Group Type ACTIVE_COMPARATOR

Spinal Anesthesia

Intervention Type PROCEDURE

Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.

Local anesthetic infusion

Intervention Type PROCEDURE

Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day

Intravenous analgesia

Intervention Type PROCEDURE

Ketorolac 30mg 3 times a day

Opioids rescue analgesia

Intervention Type PROCEDURE

Buprenorphine 0,2mg twice a day if VAS\>4

Mepivacaine 1%

Intervention Type DRUG

Levobupivacaine 0,5%

Intervention Type DRUG

Ropivacaine 0,2%

Intervention Type DRUG

Ketorolac 30mg

Intervention Type DRUG

Buprenorphine 0,2mg

Intervention Type DRUG

Stimulong, Pajunk, Germany.

Intervention Type DEVICE

Continuous lumbar plexus: non-stimulating catheter

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Continuous lumbar plexus: stimulating catheter

Perinervous stimulating catheter ("Stimulong", "Pajunk", Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia.

Intervention Type PROCEDURE

Spinal Anesthesia

Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.

Intervention Type PROCEDURE

Local anesthetic infusion

Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day

Intervention Type PROCEDURE

Intravenous analgesia

Ketorolac 30mg 3 times a day

Intervention Type PROCEDURE

Opioids rescue analgesia

Buprenorphine 0,2mg twice a day if VAS\>4

Intervention Type PROCEDURE

Mepivacaine 1%

Intervention Type DRUG

Levobupivacaine 0,5%

Intervention Type DRUG

Ropivacaine 0,2%

Intervention Type DRUG

Ketorolac 30mg

Intervention Type DRUG

Buprenorphine 0,2mg

Intervention Type DRUG

Stimulong, Pajunk, Germany.

Intervention Type DEVICE

Continuous lumbar plexus: non-stimulating catheter

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients undergoing total hip arthroplasty

Exclusion Criteria

* diabetes neurological disorders coagulation disorders rheumatoid arthritis chronic opioids therapy allergy to local anesthetic
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ASST Gaetano Pini-CTO

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gianluca Cappelleri

Medical Doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gianluca Cappelleri, M.D.

Role: PRINCIPAL_INVESTIGATOR

ASST Gaetano Pini-CTO

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Istituto ortopedico Gaetano Pini

Milan, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IOGPGC06-14

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

'The Effect of Adding LFCN Block to PENG
NCT06226675 ACTIVE_NOT_RECRUITING NA